Abbott (NYSE:ABT) won approval from the Japanese Ministry of Health, Labor and Welfare for its Xience V drug-eluting stent. Abbot said it plans to bring the device to market as soon as it receives ...

- New shorter duration of dual anti-platelet therapy (DAPT) post XIENCE stent implant provides physicians with additional options to treat patients at high risk of bleeding - XIENCE is the most used ...

NEW ORLEANS, March 24 (Reuters) - The drug-coated stent made by Abbott Laboratories Inc. demonstrated superiority over Boston Scientific Corp's top-selling Taxus stent, according to results of a ...

A clinical study has shown Abbott Laboratories' "Xience," a drug-coated stent, to be more effective than Boston Scientific's Taxus device. This result clears Abbott to seek FDA approval for the Xience ...

ABBOTT PARK, Ill., June 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced its XIENCE family of stents has received U.S. Food and Drug Administration (FDA) approval for one-month (as short as ...

Gaithersburg, MD - Seven months after an FDA advisory panel voted nine to one to recommend approval of the Xience V everolimus-eluting stent (Abbott Vascular), the FDA has granted marketing approval ...

LONDON (MarketWatch) -- Abbott ABT, +1.27% said it's going to study the Xience stent in women with previously untreated coronary artery lesions. Each year, more women than men die of cardiovascular ...

CHICAGO, June 23 (Reuters) - Abbott Laboratories on Tuesday said European regulators approved a new, more flexible version of its Xience drug-eluting stent that is designed for easier placement in the ...

"The conclusions of the trial are, in terms of angiography, that we were able to show noninferiority and superiority in terms of suppressing late loss, with strong trends toward reductions in binary ...

NATIONAL HARBOR, MD—At 3 years, the bioresorbable-polymer Orsiro stent maintains an advantage over the durable-polymer Xience, according to new data from the BIOFLOW V study. Compared with PCI ...

BARCELONA, Spain—Among all the big trials airing results at the European Society of Cardiology (ESC) Congress 2017, one tiny stent—and its performance—could have slipped through the cracks. Earlier ...

Abbott today announced its XIENCE stent has received CE Mark in Europe for shorter duration of dual antiplatelet therapy (DAPT) – as short as 28 days, the shortest indication available in the world – ...